News Briefing channel feed

Mi­cro­bio­me start­up sells off as­sets; Faron's PhI/II da­ta in bone mar­row can­cer; AM Phar­ma touts bio­mark­er re­sults

Last year
R&D

CEPI puts $25M in­to Rift Val­ley fever vac­cine; Gates in­vests in AI for sci­en­tists in Africa in eq­ui­ty bid

Last year

Bridge­Bio’s long-term limb-gir­dle mus­cu­lar dy­s­tro­phy da­ta; QHP buys a CD­MO

Last year

Re­gen­eron pays $100M mile­stone to Al­ny­lam; NIH awards Clene $45M; Bio­haven rais­es $258M

Last year

Bay­er’s projects with Twist, Evotec; Ab­b­Vie buys out Parkin­son’s drug­mak­er; A new drug dis­cov­ery non­prof­it in Toron­to

Last year

Free­line’s ear­ly Gauch­er dis­ease da­ta; Shorla rais­es $35M; Re­genxbio to start piv­otal DMD tri­al next year

Last year

Re­gen­eron ex­pands CRISPR deal with In­tel­lia; Cap­si­da, Kate's gene ther­a­py man­u­fac­tur­ing deal; Bio­haven’s $225M of­fer­ing

Last year

Rock­et’s gene ther­a­py gets a PDU­FA date; SAB Bio­ther­a­peu­tics’ $130M; Acurx to move to PhI­II

Last year

Mer­ck KGaA's ex­pand­ed AI deal; As­cle­tis has new bio­mark­er da­ta for its PD-L1; De­ka clos­es $20M round

Last year

Im­muno­van­t's $450M; On­copep­tides re­assess­es Pepax­ti strat­e­gy in Eu­rope; Ake­bia re­sub­mits kid­ney drug

Last year

Théa won't buy Pro­QR's oph­thalmic as­sets; Im­muno­vant’s $130M of­fer­ing; In­ozyme to start piv­otal study in Oc­to­ber

Last year

Pak­istan re­calls al­tered dose of Avastin; FDA re­jects Botanix gel

Last year

An­tios re­port­ed­ly shut down; Clene's long-term ALS da­ta; Keytru­da, Lenvi­ma's lung can­cer fail­ures

Last year

Pad­cev, Keytru­da’s new sur­vival da­ta; Ser­ax­is rais­es $10M for di­a­betes cell ther­a­py

Last year

He­palys to de­vel­op In­ven­ti­va’s NASH treat­ment; Ever­est li­cens­es Kezar’s au­toim­mune drug

Last year

Atara to file T cell im­munother­a­py in the US in 2024; Rayze­Bio clos­es $358M IPO

Last year

Re­Code rais­es an­oth­er $50M; His­to­gen halts clin­i­cal de­vel­op­ment; 60 De­grees with­draws Covid-19 IND

Last year

Nek­tar up­dates PhIb atopic der­mati­tis da­ta amid Lil­ly suit; Cure, Frac­etat join forces on AAV plat­form

Last year

Ab­cam founder Jonathan Mil­ner op­pos­es Dana­her buy­out; First Wave tries to find new life in Sanofi drug

Last year
AI

Sor­ren­to goes to Chi­na with Covid drug; Vista­gen touts ear­ly ef­fi­ca­cy da­ta on PMDD nasal spray

Last year

Di­anthus marks Nas­daq de­but with PhI hit; Ar­bu­tus shuts oral RNA and coro­n­avirus pro­grams

Last year

En­livex halts on­col­o­gy re­search, lays off 50% of staff; Mod­er­na warns against TRC Cap­i­tal mi­ni-ten­der

Last year

ProMIS Neu­ro­sciences se­cures $20M+ PIPE; Beam Ther­a­peu­tics re­veals da­ta ahead of IND

Last year

Vaxart re­ports mixed PhII da­ta for norovirus vac­cine; J&J to pro­ceed with Cidara in­fluen­za deal 

Last year
First page Previous page 13141516171819 Next page Last page
A service from the Financial Times